ABROCITINIB appears durable and well tolerated in patients with moderate-to-severe atopic dermatitis (AD), also known as eczema, according to a 2-year retrospective real-world study. The findings confirm sustained improvements in skin symptoms, itch, and quality of life beyond clinical trial settings.
Long-Term Clinical Outcomes Demonstrated
Previously, abrocitinib had shown promising results in randomized trials, however, real-world evidence evaluation long-term outcomes remained limited.
Investigators followed 23 patients [15 male, 8 female; mean age 29.1 (SD 11.5) years] with moderate-to-severe atopic dermatitis over two years. Key outcomes were collected at baseline and weeks 4, 12, 24, 52, and 104, including both physician and patient-reported measures: Eczema Area and Severity Index (EASI), SCORing Atopic Dermatitis (SCORAD), Investigator Global Assessment (IGA), Worst Pruritus Numeric Rating Scale (WP-NRS), Dermatology Life Quality Index (DLQI), and a stringent combined outcome of EASI90 and WP-NRS 0/1.
Over 104 weeks, mean (SD) EASI scores decreased significantly from 25.0 (SD 11.2) to 3.9 (SD 7.7) (p<0.01), while SCORAD fell from 67.2 (SD 14.1) to 9.7 (SD 19.3) (p<0.01). Nineteen patients (83%) achieved EASI75, 13 patients (57%) achieved EASI90, 12 patients (52%) achieved EASI100, and 14 patients (61%) reached IGA 0/1. Patient-reported outcomes reflected similar improvements, with 83% achieving WP-NRS 0/1 and 61% attaining DLQI <2.
Safety Profile Supports Long-Term Use
Abrocitinib was generally well tolerated. Three patients (13%) discontinued therapy due to adverse events, while remaining events were mild. Clinical and laboratory assessments confirmed no unexpected safety concerns, supporting the drug’s suitability for long-term management of moderate-to-severe atopic dermatitis.
Real-World Evidence Confirms Sustained Benefits
These findings align with prior clinical trial data, demonstrating that abrocitinib can deliver early and sustained symptom relief, reduce pruritus, and improve overall quality of life. Despite the limited sample size, the results highlight the real-world applicability of abrocitinib effectiveness and safety over a two-year period, providing clinicians with confidence in its long-term management potential.
Reference
Tsiogka A et al. Long-Term Effectiveness and Safety of Abrocitinib in Patients with Atopic Dermatitis: A Real-World, Retrospective Study. Dermatol Ther (Heidelb). 2026;DOI: 10.1007/s13555-026-01695-0. Epub ahead of print.
Featured Image: InfiniteStudio on Adobe Stock.
